Date: September 25th, 2020
Time: 12pm ET
|Tarun Kumar||Cancer Insights|
|John Methot||Dana-Farber Cancer Institute|
|Kunal Joshi||Foundation Medicine|
|Amanda Kunz||Foundation Medicine|
|Donella Bateman||Foundation Medicine|
|Peter Yu||Hartford HealthCare|
|Kerry Rowe||Intermountain Healthcare|
|Roger Mueller||Mayo Clinic|
|Wendy Ver Hoef||NCI CBIIT/Samvit Solutions|
|Trevor Pugh||Princess Margaret Cancer Centre|
|Gregory Simon||Simonovation, LLC|
|Sharon Hensley Alford||Vizlitics|
- CoP October 2020 Meeting: October 30th from 12-1pm ET
- Reach out to Anthony DiDonato via email @firstname.lastname@example.org if you would like to participate on future calls!
Planned Agenda Topics
ICAREdata Project Updates by Keri Reardon and Steven Piantadosi, Alliance.
Health economics of mCODE™ and CodeX™ by Rob Lieberthal.
Anthony DiDonato, mCODE CodeX Community Lead, kicked off the meeting with an overview of the CoP, mCODE, CodeX and with announcements.
Steve Bratt, the HL7 FHIR CodeX Project Lead, welcomed attendees and provided an update on CodeX. The American Cancer Society Cancer Action Network, the CDC, and niAnalytics are now CodeX members.
ICAREdata Project Updates - Keri Reardon and Steven Piantadosi, Alliance:
- ICAREdata = Integrating Clinical trials And Real-world Endpoints data
- The ICAREdata project includes many partners such as MITRE, Alliance, NCI, FDA, and ASCO.
- The goal is to contribute to a learning health system.
- Only 3% of patients enroll in clinical trials. Additionally, the data submitted to clinical trials is submitted through Case Report Forms (CRFs). CRF's only contain a small portion of the patient's data. However, if data for clinical trials came straight from the EHR, more data could be included in research.
- Key focuses for the study:
- Low burden on data collection
- Patient outcome data
- Typically, outcome data is found in a physician's note and is unstructured. However, this data is important for clinical trials.
- The current phase of the the study includes 3 clinical trials. In this phase, data for the trials are recorded in two different methods and the results will be compared.
- mCODE data found in the EHR
- Currently focusing on CancerDiseaseStatus and TreatmentPlanChange.
- Traditional method - CRFs.
- mCODE data found in the EHR
- The current trials are for brain metastasis, metastatic colorectal cancer, and metastatic prostate cancer.
- The team is currently looking for additional clinical trials and clinical sites to partner with.
- To partner, it is not a huge IT lift.
Health economics of mCODE™ and CodeX™ - Rob Lieberthal, MITRE:
- Economics can impact patient outcomes. For examples, patient can choose not to take medication, not go to the doctor, and it can be bad for mental health.
- Through mCODE, outcomes can improve and cost can be reduced, leading to higher value in cancer care.
- There are many different treatment combinations and pathways for cancer. NCCN guidelines cut down on the pathways, but there are still many. By having mCODE-enabled patient records, research on the effectiveness of these treatments will be able to be done more effectively.
- One CodeX use case is focused on prior authorization.
- Prior authorization pathways can be automated through mCODE, which will allow for rich, high-quality data to be easily sent.
- Insurance companies will be able to receive mCODE data elements faster and approve/deny treatment, which will increase speed of care and cut cost.
- By having comparative, mCODE records for cancer patients, more research can be conducted, leading to a higher survival rate.
Q: Can you show how Epic was configured to collect the outcome data?
A: If you're at an Epic installation and want to learn more, reach out to Keri Reardon and Dr. Piantadosi. Additionally, you can reach out to Epic Beacon contact. There is an mCODE team at Epic who can help. Additionally, the presentation for next month's CoP will be on the Epic installation.